Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)

被引:4
|
作者
Woo, Henry H. [1 ,2 ,3 ]
Khanani, Hadia [2 ]
Thompson, Nadine J. [4 ]
Sorensen, Brian J. [4 ]
Baskaranathan, Sris [2 ,3 ]
Bergersen, Philip [2 ,3 ]
Chalasani, Venu [2 ,3 ]
Dean, Thomas [2 ,3 ]
Dias, Max [2 ,3 ]
Symons, James [1 ,2 ,3 ]
Wines, Michael [2 ,3 ]
Jain, Anika [2 ]
Nassour, Anthony -Joe [2 ]
Tarlinton, Lisa C. [2 ,4 ,5 ]
机构
[1] Australian Natl Univ, Coll Hlth & Med, Canberra, Australia
[2] Sydney Adventist Hosp, SAN Prostate Ctr Excellence, Sydney, NSW, Australia
[3] Sydney Adventist Hosp, Dept Urol, Sydney, NSW, Australia
[4] Sydney Adventist Hosp, SAN Radiol & Nucl Med, Sydney, NSW, Australia
[5] Sydney Adventist Hosp, SAN Radiol & Nucl Med, 185 Fox Rd, Wahroonga, NSW 2076, Australia
来源
EUROPEAN UROLOGY OPEN SCIENCE | 2023年 / 47卷
关键词
Magnetic resonance imaging; Positron emission tomography; Prostate biopsy; Prostate cancer; Prostate -specific membrane; antigen; DIAGNOSTIC CERTAINTY; LEXICON;
D O I
10.1016/j.euros.2022.11.012
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computerised tomography (PET/CT) is increasingly being utilised in the diagnostic pathway for prostate cancer (PCa). Recent publications have sug-gested that this might help identify those who can avoid biopsy.Objective: The primary objective of this study was to determine whether PET mag-netic resonance imaging (MRI) fusion could negate the need to biopsy prior to prostatectomy in a selected population of men.Design, setting, and participant: Multiparametric MRI (mpMRI) for PCa is our stan-dard of care prior to prostate biopsy. Biopsy-naive men with one or more Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesions >10 mm on mpMRI were invited to undergo PSMA PET/CT prior to biopsy. Following ethics approval, 60 men were recruited between September 2020 and March 2021. The key exclusion criteria included a previous history of PCa and previous prostate sur-gery or biopsy.Outcome measurements and statistical analysis: A positive PET MRI fusion scan was defined as "consistent with"as per the Memorial Sloan Kettering Cancer Center lexicon of certainty, and concordance with biopsy results was analysed. Clinically significant PCa (csPCa) was defined as grade group (GG) >= 2 on pathology. A chi-square analysis was performed with statistical significance defined at p < 0.05.Results and limitations: A total of 71 mpMRI lesions were positive on 61 (86%) PET MRI fusion scans. Fifty-nine of 61 lesions biopsied confirmed csPCa in 54 (92%). Of five of 59 lesions for which either biopsy was negative or low-grade cancer was found, three had rebiopsy of which two were confirmed to have csPCa corroborating with PET MRI fusion and one was reconfirmed to have GG1 only. For the remaining two, both had another lesion elsewhere in the gland confirming csPCa, and hence rebiopsy was not performed. Ultimately, 56 of 59 (95%) lesions with a positive PET MRI fusion scan were confirmed to have csPCa. All GG >3 can-cers had a positive PET MRI fusion scan. Conclusions: This prospective study of PET MRI fusion assessment of men with PI-RADS 4 or 5 lesion >10 mm on mpMRI confirms that the majority of men (95%) with a positive PET MRI fusion scan will have csPCa. This supports recently pub-lished retrospective data suggesting that selected men might avoid prostate biopsy prior to radical prostatectomy.Patient summary: In this research, we have confirmed that prostate-specific mem-brane antigen positron emission tomography/computerised tomography in combi-nation with magnetic resonance imaging could have an important role in enabling a diagnosis of prostate cancer. Using the combination of these scans, we could con-fidently predict the presence of aggressive prostate cancer in some men for which treatment is warranted. This means that there are some men who could possibility proceed directly to having prostate cancer surgery without the need for a confirma-tory prostate biopsy.(c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [1] The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature
    Manfredi, Celeste
    Fernandez-Pascual, Esau
    Arcaniolo, Davide
    Emberton, Mark
    Sanchez-Salas, Rafael
    Guix, Carlos Artigas
    Bianco, Fernando
    Cathcart, Paul
    Murphy, Declan G.
    Counago, Felipe
    Martinez-Ballesteros, Claudio
    Verze, Paolo
    Ignacio Martinez-Salamanca, Juan
    EUROPEAN UROLOGY FOCUS, 2022, 8 (04): : 942 - 957
  • [2] New frontiers in focal therapy for prostate cancer: Prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging
    Manfredi, Celeste
    Fernandez-Pascual, Esau
    Linares-Espinos, Estefania
    Counago, Felipe
    Martinez-Salamanca, Juan Ignacio
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (02): : 61 - 68
  • [3] Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology
    Kalapara, Arveen A.
    Ballok, Zita E.
    Ramdave, Shakher
    O'Sullivan, Richard
    Ryan, Andrew
    Konety, Badrinath
    Grummet, Jeremy P.
    Frydenberg, Mark
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (03): : 314 - 320
  • [4] Radical Prostatectomy without Prior Biopsy in Patients with High Suspicion of Prostate Cancer Based on Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen Positron Emission Tomography: A Prospective Cohort Study
    Chaloupka, Michael
    Apfelbeck, Maria
    Pyrgidis, Nikolaos
    Marcon, Julian
    Weinhold, Philipp
    Stief, Christian G.
    CANCERS, 2023, 15 (04)
  • [5] A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
    Kelly, Brian D.
    Ptasznik, Gideon
    Roberts, Matthew J.
    Doan, Paul
    Stricker, Phillip
    Thompson, James
    Buteau, James
    Chen, Kenneth
    Alghazo, Omar
    O'Brien, Jonathan S.
    Hofman, Michael S.
    Frydenberg, Mark
    Lawrentschuk, Nathan
    Lundon, Dara
    Murphy, Declan G.
    Emmett, Louise
    Moon, Daniel
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 53 : 90 - 97
  • [6] Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy
    Geboers, Bart
    Meijer, Dennie
    Counter, William
    Blazevski, Alexandar
    Thompson, James
    Doan, Paul
    Gondoputro, William
    Katelaris, Athos
    Haynes, Anne-Maree
    Delprado, Warick
    O'Neill, Gordon
    Yuen, Carlo
    Vis, Andre N.
    van Leeuwen, Pim J.
    Ho, Bao
    Liu, Victor
    Lee, Jonathan
    Donswijk, Maarten L.
    Oprea-Lager, Daniela
    Scheltema, Matthijs J.
    Emmett, Louise
    Stricker, Phillip D.
    BJU INTERNATIONAL, 2024, 133 : 14 - 22
  • [7] The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
    Emmett, Louise
    Buteau, James
    Papa, Nathan
    Moon, Daniel
    Thompson, James
    Roberts, Matthew J.
    Rasiah, Kris
    Pattison, David A.
    Yaxley, John
    Thomas, Paul
    Hutton, Anthony C.
    Agrawal, Shikha
    Amin, Amer
    Blazevski, Alexandar
    Chalasani, Venu
    Ho, Bao
    Nguyen, Andrew
    Liu, Victor
    Lee, Jonathan
    Sheehan-Dare, Gemma
    Kooner, Raji
    Coughlin, Geoff
    Chan, Lyn
    Cusick, Thomas
    Namdarian, Benjamin
    Kapoor, Jada
    Alghazo, Omar
    Woo, Henry H.
    Lawrentschuk, Nathan
    Murphy, Declan
    Hofman, Michael S.
    Stricker, Phillip
    EUROPEAN UROLOGY, 2021, 80 (06) : 682 - 689
  • [8] Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer
    Rhee, H.
    Thomas, P.
    Shepherd, B.
    Gustafson, S.
    Vela, I.
    Russell, P. J.
    Nelson, C.
    Chung, E.
    Wood, G.
    Malone, G.
    Wood, S.
    Heathcote, P.
    JOURNAL OF UROLOGY, 2016, 196 (04) : 1261 - 1266
  • [9] Microcosting Study of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Prostate Cancer
    Parkinson, Bonny
    Sharma, Rajan
    Jeet, Varinder
    Song, Rachel
    Hoyle, Martin
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 17 - 22
  • [10] Research progress on prostate-specific membrane antigen ligand positron emission tomography imaging of prostate cancer
    Li Y.
    Liu B.
    Yuan Y.
    Qin W.
    Shengwu Yixue Gongchengxue Zazhi/Journal of Biomedical Engineering, 2022, 39 (06): : 1263 - 1268